Yale Finds 44-Cent Drug May Help Some With Autism

A drug that costs less than 50 cents per pill could help some people with autism spectrum disorder live with fewer symptoms, according to new research from Yale University.

Scientists tested 774 FDA-approved drugs on zebrafish genetically modified to show autism-like behaviors. They narrowed the list to 520 non-toxic options with promising effects, and one drug stood out: levocarnitine, sold as Carnitor.

The choice of zebrafish might seem odd, but these tiny swimmers are research powerhouses. They share 70% of our genes, and 84% of genes linked to human diseases have equivalents in zebrafish, making them perfect for studying everything from epilepsy to Parkinson's disease.

Levocarnitine currently treats low carnitine levels, helping the body convert food into energy. But the Yale team found it does something more in zebrafish with mutations in two genes tied to autism: SCN2A and DYRK1A.

The drug helped restore more typical behavior patterns in the modified fish. It also promoted balanced metabolism and more normal brain activity, appearing to reverse disruptive behaviors.

Here's the important caveat: these specific genetic mutations are rare. SCN2A appears in roughly 1 in 333 autism cases, while DYRK1A mutations affect fewer than 1% of people diagnosed with autism spectrum disorder.

That means levocarnitine would likely only help a small subset of people with autism who carry these particular mutations. Still, researchers say that's exactly why this matters.

More than 800 autism risk genes have been identified so far. The Yale team created an open-source, searchable database of their drug findings to help other scientists pursue similar discoveries for different genetic profiles.

Why This Inspires

This research represents a shift in how scientists think about autism treatment. Rather than looking for one universal solution, they're recognizing that autism has many different genetic roots requiring different approaches.

The 44-cent price tag matters too. Affordable treatments mean more families could access help if the drug proves effective in human trials.

As autism diagnoses have climbed from 1 in 150 children in 2000 to 1 in 31 by 2022, the need for treatment options has grown urgent. Scientists credit better screening and awareness for the increase, not an actual rise in cases.

Dr. Ellen Hoffman, the study's senior author and a psychiatric geneticist, emphasized that the drug still needs human testing. Families should not seek it out as a treatment yet.

But the foundation is laid. Every autism risk gene studied brings researchers closer to personalized treatments that could help specific groups of people thrive.